Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK129 Combined With Chemotherapy With or Without Cadonilimab in Advanced HER2 Negative Gastric or GEJ Adenocarcinoma
NCT06586294Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2024
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AK129 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Sep 2024; status: completed.
02
Drugs
AK129
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06586294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586294.